公开(公告)号：US11584717B2

公开(公告)日：2023-02-21

申请号：US16229069

申请日：2018-12-21

申请人： YALE UNIVERSITY

发明人： William L. Jorgensen ,  Richard J. Bucala

IPC分类号： C07D209/18 ,  C07D235/12 ,  C07D235/24 ,  C07D249/06 ,  C07D263/58 ,  C07D275/04 ,  C07D307/80 ,  C07D307/83 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D405/06 ,  C07D413/04 ,  C07D417/04

摘要： The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

公开(公告)号：US11578065B2

公开(公告)日：2023-02-14

申请号：US16646980

申请日：2018-09-04

申请人： HODOGAYA CHEMICAL CO., LTD.

发明人： Kazuyuki Suruga ,  Takeshi Yamamoto ,  Kouki Kase ,  Shunji Mochizuki

IPC分类号： C07D413/10 ,  C07D413/04 ,  C07C211/54 ,  C07C211/58 ,  C07D209/82 ,  C07D263/57 ,  C07D277/66 ,  C07D307/91 ,  C07D333/76 ,  C07D413/14 ,  C07D417/04 ,  C07D417/10 ,  C07D417/14 ,  H01L51/00 ,  H01L51/42

摘要： An organic EL device is provided, including at least an anode, a hole transport layer, a light-emitting layer, an electron transport layer, and a cathode in this order, wherein the hole transport layer contains an arylamine compound represented by the following formula (1), wherein Ar1 to Ar8 and n1 are defined in the specification, and the electron transport layer contains a compound having a benzoazole ring structure represented by the following formula (2), wherein Ar9, Ar10, X, Y1, Z1 and Z2 are defined in the specification.

公开(公告)号：US20230040251A1

公开(公告)日：2023-02-09

申请号：US17947260

申请日：2022-09-19

申请人： YUNBAIYAO ZHENGWU SCIENTIFIC (SHANGHAI) CO. LTD.

发明人： Zhengwu SHEN

IPC分类号： C07D413/04 ,  A61K45/06 ,  A61P35/00

摘要： Disclosed are a benzimidazole derivative of formula (I), or an isomer, a pharmaceutically-acceptable salt, or a prodrug thereof, and a preparation thereof. An application of the benzimidazole derivative in the treatment of tumors is further provided.

公开(公告)号：US20230029852A1

公开(公告)日：2023-02-02

申请号：US17855414

申请日：2022-06-30

申请人： Tesla, Inc.

发明人： David S. Hall ,  Jeffery Raymond Dahn ,  Toren Hynes

IPC分类号： C07D273/01 ,  C07D413/04

摘要： Provided are methods of preparing 3-R-1,4,2-dioxazol-5-one compounds using convenient and efficient methods. Also provided are 3-R-1,4,2-dioxazol-5-one compounds produced using the methods described.

公开(公告)号：US20230027929A1

公开(公告)日：2023-01-26

申请号：US17773404

申请日：2020-11-05

申请人： Dermira, Inc.

发明人： Ferda Cevikbas ,  Christopher Pearson ,  Donnya Etheridge ,  Laura Gleave ,  Mark Duggan ,  Nina Connelly Ursinyova ,  Vasileios Roumpelakis

IPC分类号： C07D213/75 ,  A61K31/4412 ,  A61K31/4433 ,  C07D405/12 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4439 ,  C07D401/12 ,  A61K31/4427 ,  C07D413/04 ,  C07D241/20 ,  A61K31/4965 ,  A61K31/436 ,  C07D498/04 ,  C07D239/47 ,  A61K31/513 ,  A61K31/506 ,  C07D403/12 ,  C07D403/04 ,  C07D401/06 ,  A61K9/00

摘要： The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.

公开(公告)号：US20230019060A1

公开(公告)日：2023-01-19

申请号：US17465583

申请日：2021-09-02

申请人： C4 Therapeutics, Inc.

发明人： Christopher G. Nasveschuk ,  Roger Norcross ,  Fabian Dey ,  Annick Goergler ,  Eric Kusznir

IPC分类号： C07D413/04 ,  C07D403/04 ,  C07D471/04 ,  C07D417/04

摘要： The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20230014137A1

公开(公告)日：2023-01-19

申请号：US17779260

申请日：2020-11-27

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Yuzo IWAKI ,  Toshimitsu ENDO ,  Kensuke KUSUMI

IPC分类号： C07D207/22 ,  C07D207/34 ,  C07D471/04 ,  C07D495/04 ,  C07D209/70 ,  C07D409/12 ,  C07D417/04 ,  C07D405/04 ,  C07D513/04 ,  C07D487/04 ,  C07F9/572 ,  C07D403/04 ,  C07D413/04

摘要： A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY): wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.

公开(公告)号：US20220372026A1

公开(公告)日：2022-11-24

申请号：US17761829

申请日：2020-09-17

申请人： SYNGENTA CROP PROTECTION AG

发明人： Vikas SIKERVAR ,  Indira SEN ,  Michel MUEHLEBACH ,  Sebastian RENDLER ,  André STOLLER ,  Daniel EMERY ,  Anke BUCHHOLZ ,  Benedikt KURTZ

IPC分类号： C07D413/04 ,  C07D471/04 ,  C07D401/04 ,  C07D413/14

摘要： Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling animal pests, including arthropods and in particular insects or representatives of the order Acarina.

公开(公告)号：US11505559B2

公开(公告)日：2022-11-22

申请号：US16760345

申请日：2018-10-30

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  YALE UNIVERSITY

发明人： Shyh Ming Yang ,  David J. Maloney ,  Natalia Martinez ,  Adam Yasgar ,  Anton Simeonov ,  Vasilis Vasiliou

IPC分类号： C07D491/113 ,  C07D401/14 ,  C07D401/12 ,  C07D215/54 ,  C07D491/107 ,  C07D413/04 ,  C07D519/00 ,  C07D401/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10 ,  C07D401/06 ,  C07D409/14

摘要： The disclosure provides compounds of Formula I, which may be useful as aldehyde dehydrogenase inhibitors and the pharmaceutically acceptable salts thereof. The variables, J, R4, G, Q, and ring A are defined herein. Aldehyde dehydrogenase inhibitors of Formula I are useful for treating a variety of conditions including cancer and inflammation. The disclosure includes methods for using compounds and salts of Formula I to treat colon cancer, pancreatic cancer, nasopharyngeal carcinoma, thyroid cancer, prostate cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, hepatocellular carcinoma, leukemia, brain tumors breast cancer, atherosclerosis, ischaemic heart disease, acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, chronic prostatitis, glomerulonephritis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis. The disclosure also includes pharmaceutical compositions containing a compound or salt of Formula I.

公开(公告)号：US11505532B2

公开(公告)日：2022-11-22

申请号：US17191161

申请日：2021-03-03

申请人： SHANDONG DANHONG PHARMACEUTICAL CO., LTD.

发明人： Zhi Luo ,  Xiaolin Li ,  Yaxun Yang ,  Lele Yang ,  Peng Li ,  Haiying He ,  Jian Li ,  Shuhui Chen

IPC分类号： C07D271/10 ,  A61P1/16 ,  C07D231/12 ,  C07D235/18 ,  C07D239/08 ,  C07D239/26 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D261/20 ,  C07D263/57 ,  C07D271/06 ,  C07D277/24 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04

摘要： The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof.